Veerhealth Care Clinches USFDA Nod, Set to Export OTC Drugs to USA with Major Orders in Pipeline

Veerhealth Care Ltd has achieved a pivotal milestone, successfully closing a USFDA inspection and qualifying to export over-the-counter (OTC) drugs to the United States. This regulatory breakthrough not only validates the company’s manufacturing standards but also unlocks significant growth opportunities in the lucrative US healthcare market.

 

Key Highlights:

 

USFDA Green Light: Veerhealth Care completed the USFDA’s Form 4003 pre-inspection records request, receiving confirmation that no further action is required. This regulatory clearance enables the company to export its oral care and ayurvedic OTC products to the US, boosting its global credibility and market access.

 

Export Orders Secured: The company has already secured export orders worth $197,793 (about ₹1.65 crore) from a leading US institutional supplier, following successful sample shipments. Additional orders, including one worth $106,673, are in the pipeline, with expectations of monthly repeat business from US clients, potentially reaching annual orders of ₹18 crore.

 

Production Expansion: To meet rising demand, Veerhealth Care is expanding its Vapi, Gujarat facility to a larger, USFDA- and WHO-compliant plant. A ₹33 crore investment is underway to scale up capacity and infrastructure, positioning the company for sustained international growth.

 

Financial Ambitions: Management projects revenues of ₹100 crore with a 10% PAT margin within the next 2–3 years, driven by robust export momentum and a growing client base in the US.

 

Strategic Partnerships: The company’s strong relationships with institutional buyers and a focus on pure vegetarian, ayurvedic formulations further differentiate its offerings in the competitive US OTC market.

 

With regulatory clearance and a swelling export order book, Veerhealth Care is poised for a transformative leap in the global healthcare arena.

 

Sources: The Hindu Business Line, Business Standard, Indian Pharma Post, NDTV Profit